1. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
- Author
-
Martina Greco, Valentina Calò, Sergio Rizzo, Alessandro Perez, F. Iacono, Sara Inguglia, Stefania Cusenza, Gianni Pantuso, Delia Sardo, L. Insalaco, Lorena Incorvaia, Marta Castiglia, Marco Bono, Valerio Gristina, Antonio Galvano, Maria La Mantia, Katia Calcara, Antonio Russo, Giulia Santanelli, Maria Chiara Lisanti, L. Castellana, Sofia Cutaia, Nadia Barraco, V. Bazan, Gristina, Valerio, La Mantia, Maria, Galvano, Antonio, Cutaia, Sofia, Barraco, Nadia, Castiglia, Marta, Perez, Alessandro, Bono, Marco, Iacono, Federica, Greco, Martina, Calcara, Katia, Calò, Valentina, Rizzo, Sergio, Incorvaia, Lorena, Lisanti, Maria Chiara, Santanelli, Giulia, Sardo, Delia, Inguglia, Sara, Insalaco, Lavinia, Castellana, Luisa, Cusenza, Stefania, Pantuso, Gianni, Russo, Antonio, and Bazan, Viviana
- Subjects
0301 basic medicine ,EGFR ,NSCLC ,03 medical and health sciences ,0302 clinical medicine ,systematic review ,Pathology ,RB1-214 ,Medicine ,Epidermal growth factor receptor ,Lung cancer ,Pathological ,biology ,business.industry ,medicine.disease ,respiratory tract diseases ,concurrent genomic alteration ,Critical appraisal ,030104 developmental biology ,Lung cancer cell ,concurrent genomic alterations ,NGS ,030220 oncology & carcinogenesis ,Concomitant ,Cancer research ,biology.protein ,Non small cell ,business ,Tyrosine kinase - Abstract
The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically altered the treatment approach for patients with metastatic non-small cell lung cancer (NSCLC). Latest investigations by using next-generation sequencing (NGS) have shown that other oncogenic driver mutations, believed mutually exclusive for decades, could coexist in EGFR-mutated NSCLC patients. However, the exact clinical and pathological role of concomitant genomic aberrations needs to be investigated. In this systematic review, we aimed to summarize the recent data on the oncogenic role of concurrent genomic alterations, by specifically evaluating the characteristics, the pathological significance, and their potential impact on the treatment approach.
- Published
- 2021
- Full Text
- View/download PDF